Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Akrimax Pharmaceuticals (InnoPran XL Marketing Authorization Rights)

M&A STATUS
Buyout/LBO LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Marketing authorization rights of a pharmaceutical product in the United States. The property is the United States marketing authorization rights to a beta blocker pharmaceutical product indicated for the treatment of hypertension to lower blood pressure.

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Primary Office
  • 11 Commerce Drive
  • Cranford, NJ 07016
  • United States

Akrimax Pharmaceuticals (InnoPran XL Marketing Authorization Rights) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Akrimax Pharmaceuticals (InnoPran XL Marketing Authorization Rights)‘s full profile, request access.

Request full access to PitchBook

Akrimax Pharmaceuticals (InnoPran XL Marketing Authorization Rights) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Akrimax Pharmaceuticals (InnoPran XL Marketing Authorization Rights)‘s full profile, request access.

Request full access to PitchBook